Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Abbott Laboratories’s stock clocked out at $128.05, up 0.68% from its previous closing price of $127.19. In other words, the price has increased by $0.68 from its previous closing price. On the day, 8.03 million shares were traded. ABT stock price reached its highest trading level at $128.81 during the session, while it also had its lowest trading level at $126.23.
Ratios:
To gain a deeper understanding of ABT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 28.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.19. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.70. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In the most recent recommendation for this company, The Benchmark Company on October 10, 2025, initiated with a Buy rating and assigned the stock a target price of $145.
On July 18, 2025, Jefferies Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $145. On June 16, 2025, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $143.Leerink Partners initiated its Market Perform rating on June 16, 2025, with a $143 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 25 ’25 when Shroff Eric sold 1,586 shares for $128.02 per share. The transaction valued at 203,043 led to the insider holds 30,384 shares of the business.
Eric Shroff bought 1,586 shares of ABT for $203,042 on Nov 25 ’25. On Aug 08 ’25, another insider, Boudreau Philip P, who serves as the EVP AND CFO of the company, sold 5,550 shares for $134.55 each. As a result, the insider received 746,758 and left with 51,003 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABT now has a Market Capitalization of 222865784832 and an Enterprise Value of 228214554624. As of this moment, Abbott’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.06, and their Forward P/E ratio for the next fiscal year is 22.60. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.08 while its Price-to-Book (P/B) ratio in mrq is 4.37. Its current Enterprise Value per Revenue stands at 5.205 whereas that against EBITDA is 19.427.
Stock Price History:
The Beta on a monthly basis for ABT is 0.71, which has changed by 0.06927276 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, ABT has reached a high of $141.23, while it has fallen to a 52-week low of $110.86. The 50-Day Moving Average of the stock is -1.33%, while the 200-Day Moving Average is calculated to be -2.29%.
Shares Statistics:
It appears that ABT traded 6.14M shares on average per day over the past three months and 8043890 shares per day over the past ten days. A total of 1.74B shares are outstanding, with a floating share count of 1.73B. Insiders hold about 0.69% of the company’s shares, while institutions hold 80.55% stake in the company. Shares short for ABT as of 1763078400 were 19141411 with a Short Ratio of 3.28, compared to 1760486400 on 19360135. Therefore, it implies a Short% of Shares Outstanding of 19141411 and a Short% of Float of 1.11.
Dividends & Splits
With its trailing 12-month dividend rate of 2.36, ABT has a forward annual dividend rate of 2.36. Against a Trailing Annual Dividend Yield of 0.018554917. The stock’s 5-year Average Dividend Yield is 1.71. . The current Payout Ratio is 29.33% for ABT, which recently paid a dividend on 2025-10-15 with an ex-dividend date of 2025-10-15. Stock splits for the company last occurred on 2013-01-02 when the company split stock in a 10000:4798 ratio.
Earnings Estimates
Abbott Laboratories (ABT) is currently under the scrutiny of 24.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $1.2, with high estimates of $1.3 and low estimates of $1.14.
Analysts are recommending an EPS of between $5.2 and $5.14 for the fiscal current year, implying an average EPS of $5.15. EPS for the following year is $5.68, with 28.0 analysts recommending between $5.85 and $5.51.
Revenue Estimates
In . The current quarter, 24 analysts expect revenue to total $11.8B. It ranges from a high estimate of $11.87B to a low estimate of $11.71B. As of . The current estimate, Abbott Laboratories’s year-ago sales were $10.97BFor the next quarter, 24 analysts are estimating revenue of $11.19B. There is a high estimate of $11.52B for the next quarter, whereas the lowest estimate is $10.92B.
A total of 28 analysts have provided revenue estimates for ABT’s current fiscal year. The highest revenue estimate was $44.84B, while the lowest revenue estimate was $44.58B, resulting in an average revenue estimate of $44.67B. In the same quarter a year ago, actual revenue was $41.95BBased on 28 analysts’ estimates, the company’s revenue will be $48.22B in the next fiscal year. The high estimate is $50.47B and the low estimate is $47.11B.
